Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

BofA lowered the firm’s price target on Arvinas (ARVN) to $28 from $54 and keeps a Buy rating on the shares after the Phase 3 VERITAC-2 trial ...

On Tuesday, based on data from those with estrogen receptor 1 (ESR1m) mutations, the duo said that the protein degrader reached the primary endpoint in their Phase 3 VERITAC-2 trial designed to ...

The 624-subject global study evaluated patients’ progression-free survival (PFS) as a primary endpoint in the intent-to-treat and estrogen receptor 1-mutant (ESR1m) populations, while their ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...